Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) (NCT02227199)
This phase I/II trial studies the side effects and best dose of brentuximab vedotin (also known as SGN-035) that can be combined with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory).
Monoclonal antibody-drug conjugates or ADCs, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
It is expected that giving brentuximab vedotin together with an ifosfamide, carboplatin, and etoposide chemotherapy regimen may kill more cancer cells.
This trial is sponsored by the University of Washington/ National Cancer Institute (NCI). 
- Condition: Hodgkin Lymphoma
- Other: Laboratory Biomarker Analysis
- Phase: I & II
- Estimated Enrollment: 30
- Start: October 2014
- Estimated Primary Completion: September 2018 (Final data collection date for primary outcome measure
- Last verified: April 2015
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.